Hospital

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses what the SHC’s diabetes DRIVE toolkit is and how it helps to address disparities in diabetes disease burden and health outcomes.

Sarah Temkin, MD, of the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses how the NIH ORWH has helped to advance clinical research on biological and sociological variables.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.

David Olson, PhD, the chief innovation officer, head of scientific advisory board, and co-founder of delix therapeutics and an associate professor at University of California, Davis, discusses psychedelics and other psychoplastogens in the treatment of brain and mental health disorders.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Bladder cancer risk increases with age and is more common among men than women.

Study suggests that emergency physicians prescribe naloxone to patients who overdose.

Common triggers for atrial fibrillation include alcohol, caffeine, and less sleep.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, explains how pharmacists and USP came together in 2021 to work harder than ever before, as well as what can be done now to prepare for the next health crisis.

Pharmacists play an important role in educating patients and other health care practitioners on the signs and symptoms of C. difficile infection.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Modern technology is crucial to the provision of home infusions.

Immunocompromised individuals are at a higher risk of developing severe symptoms and dying from COVID-19.

Vraylar is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia and for manic, mixed, or depressive episodes for patients with bipolar I disorder.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses the challenges that lie ahead as we move into the third year of the COVID-19 pandemic, as well as other major developments on the horizon for pharmacists in 2022.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the primary endpoint in the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.

The cancer care system lags in comparison to other chronic health conditions in this key area.

Bevespi is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses what stands out as the biggest challenge from the past year and what role USP and pharmacists had in overcoming that challenge.

Luciano Costa, MD, PhD, associate director for clinical research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, on the safety and efficacy of Dara-KRd in the treatment of patients with newly diagnosed multiple myeloma.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, addresses the primary endpoint in the trial assessing zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.

Mean changes from baseline in weight, fasting glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were similar between lumateperone and placebo.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses how the work of the NIH ORWH impacts pharmacy practice.

The Board of Trustees of APhA addresses 5 areas in their statement, including importance of wellbeing, root causes of pharmacist burnout, pharmacy benefit manager issues, need for provider status, and some potential solutions.

The updated oath has entered into the modern era with more inclusive and contemporary language.

Help patients choose appropriate medications and direct them to a physician, when necessary

Although marginal zone lymphoma is relatively rare, it contains a broad spectrum of conditions under it that require an individualized treatment selection process.